SCHEMBL402502

SCHEMBL402502

CC(=O)CCC(=O)OCC(O)CO

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.61
DUSP3 P51452 1/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
LMNA P02545 1/20 0.61
DGKA P23743 1/20 0.51
FAAH O00519 4/20 0.49
ALDH1A1 P00352 1/20 0.40
PRKCA P17252 3/20 0.39
LPAR6 P43657 1/20 0.38
LPAR1 Q92633 1/20 0.38
LPAR4 Q99677 1/20 0.38
LPAR5 Q9H1C0 1/20 0.38
LPAR2 Q9HBW0 1/20 0.38
LPAR3 Q9UBY5 1/20 0.38
ENPP2 Q13822 1/20 0.38
MAPT P10636 1/20 0.38
CNR2 P34972 3/20 0.38
PRKCE Q02156 1/20 0.38
PRKCQ Q04759 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL460659 0.98 KDM4E (0.59) KDM4EDUSP3MEN1KMT2ALMNA
Acetic Acid SCHEMBL27929017 0.90 KDM4E (0.62) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL16580803 0.90 LMNA (0.47) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL236697 0.89 LMNA (0.66) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL18608202 0.89 KDM4E (0.67) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL443865 0.87 KDM4E (0.75) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL6441580 0.87 KDM4E (0.75) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL447046 0.87 KDM4E (0.75) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL6446791 0.87 KDM4E (0.75) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL447477 0.87 KDM4E (0.75) KDM4EDUSP3MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-220968157-U Joint separation device for acetonide and glycerate acetate 山东衡兴新材料科技有限公司 2024-05-17 CN claimed
CN-110526894-B Method for synthesizing acetone-glycerol acetate from glycerol 浙江工业大学 2020-11-17 CN claimed
CN-110872539-A Method for preparing water-based lubricating oil by utilizing levulinic acid 北京化工大学 2020-03-10 CN claimed
CN-107075094-A High recycle content polyester polyols from hydroxy-functional ketal acids, esters or amides 树脂酸盐材料集团有限公司 2017-08-18 CN claimed
CN-105085170-A Method for preparing 1,3-propylene glycol and gamma-valerolactone from glycerin and acetylpropionic acid by one-step method UNIV NANKAI 2015-11-25 CN claimed
US-20100312006-A1 PRODUCTION OF LEVULINIC ACID AND LEVULINATE ESTERS FROM BIOMASS MEADWESTVACO CORPORATION (US) 2010-12-09 US claimed
EP-4610288-A1 POLYMER PARTICLES WITH LIQUID ACTIVE MATERIALS IN CORE Lalgudi, Ramanathan S. (US) 2025-09-03 EP disclosed
EP-4448665-A1 BIO-BASED POLYOLS, ESTERS, AND SURFACTANTS Lalgudi, Ramanathan S. (US) 2024-10-23 EP disclosed
US-20240254272-A1 BIO-BASED POLYOLS, ESTERS, AND SURFACTANTS LALGUDI RAMANATHAN S (US) 2024-08-01 US disclosed
CN-220968157-U Joint separation device for acetonide and glycerate acetate 山东衡兴新材料科技有限公司 2024-05-17 CN disclosed
US-11932721-B2 Bio-based polyols, esters, and surfactants Lalgudi, Ramanathan S. (US) 2024-03-19 US disclosed
CN-116669553-A Lactam composition and use 联合利华知识产权控股有限公司 2023-08-29 CN disclosed
WO-2023114250-A1 BIO-BASED POLYOLS, ESTERS, AND SURFACTANTS LALGUDI RAMANATHAN S (US) 2023-06-22 WO disclosed
EP-1404873-A2 CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME Dynavax Technologies Corporation (US) 2004-04-07 EP disclosed
US-20030199466-A1 For modulating an immune response DYNAVAX TECHNOLOGIES CORPORATION 2003-10-23 US disclosed
US-20030175731-A1 Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies DYNAVAX TECHNOLOGIES CORPORATION 2003-09-18 US disclosed
WO-2003000922-A2 CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME DYNAVAX TECHNOLOGIES CORPORATION (US) 2003-01-03 WO disclosed
US-6326487-B1 OLIGONUCLEOTIDES, ANTISENSE AGENTS, VIRICIDES AND GENE EXPRESSION AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-12-04 US disclosed
US-5696248-A GENE EXPRESSION INHIBITOR, AS PROBES FOR DETECTING NUCLEIC ACIDS, AS VIRICIDES TREATING VIRAL DISEASE CAUSED BY HTLV, INFLUENZA, HEPATITIS VIRUS, PAPILLOMA VIRUS HOECHST AKTIENGESELLSCHAFT (DE) 1997-12-09 US disclosed
EP-0688784-A2 3'-Modified oligonucleotide derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1995-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199466-A1 For modulating an immune response IFNG, ICOS, CD47 KDM4E 1282/4885DUSP3 244/4885MEN1 3937/4885
US-20030175731-A1 Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies TSLP, CD74, MICA KDM4E 4540/4885DUSP3 1866/4885MEN1 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.